Silke Frahm, V. Mautner, H. Brems, E. Legius, M. Debiec-Rychter, R. Friedrich, W. Knöfel, M. Peiper, L. Kluwe (2004)
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patientsNeurobiology of Disease, 16
S. Huson (1993)
Neurofibromatosis: Phenotype, Natural History and PathogenesisJournal of Medical Genetics, 30
M. Neshat, I. Mellinghoff, C. Tran, B. Stiles, G. Thomas, Roseann Petersen, P. Frost, J. Gibbons, Hong Wu, C. Sawyers (2001)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTORProceedings of the National Academy of Sciences of the United States of America, 98
X. Ming, B. Burgering, Stefan Wennstrom, L. Claesson-Welsh, C. Heldin, J. Bos, S. Kozma, G. Thomas (1994)
Activation of p70/p85 S6 kinase by a pathway independent of p21fi rasNature, 371
E. Serra, T. Rosenbaum, Ursula Winner, R. Aledo, E. Ars, X. Estivill, H. Lenard, C. Lázaro (2000)
Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations.Human molecular genetics, 9 20
T. Basu, D. Gutmann, J. Fletcher, T. Glover, F. Collins, J. Downward (1992)
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patientsNature, 356
Andrew Tee, B. Manning, Philippe Roux, L. Cantley, J. Blenis (2003)
Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward RhebCurrent Biology, 13
W. Hahn, R. Weinberg (2002)
Modelling the molecular circuitry of cancerNature Reviews Cancer, 2
B. Raught, A. Gingras, N. Sonenberg (2001)
The target of rapamycin (TOR) proteinsProceedings of the National Academy of Sciences of the United States of America, 98
V. Riccardi (1993)
Neurofibromatosis: Phenotype, Natural History and PathogenesisPlastic and Reconstructive Surgery, 91
Philippe Roux, B. Ballif, R. Anjum, S. Gygi, J. Blenis (2004)
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.Proceedings of the National Academy of Sciences of the United States of America, 101 37
K. Cichowski, T. Shih, E. Schmitt, S. Santiago, Karlyne Reilly, M. Mclaughlin, R. Bronson, T. Jacks (1999)
Mouse models of tumor development in neurofibromatosis type 1.Science, 286 5447
K. Inoki, Yong Li, Tian Zhu, Jun Wu, K. Guan (2002)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signallingNature Cell Biology, 4
Haesun Kim, T. Rosenbaum, Marchionni Ma, N. Ratner, D. Je (1995)
Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes.Oncogene, 11 2
K. Cichowski, T. Jacks (2001)
NF1 Tumor Suppressor Gene Function Narrowing the GAPCell, 104
J. Bader (1986)
Neurofibromatosis and CancerAnnals of the New York Academy of Sciences, 486
D. Fingar, J. Blenis (2004)
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progressionOncogene, 23
T. Rosenbaum, C. Rosenbaum, Ursula Winner, H. Müller, H. Lenard, C. Hanemann (2000)
Long‐term culture and characterization of human neurofibroma‐derived Schwann cellsJournal of Neuroscience Research, 61
R. Shaw, N. Bardeesy, B. Manning, L. Lopez, Monica Kosmatka, R. DePinho, L. Cantley (2004)
The LKB1 tumor suppressor negatively regulates mTOR signaling.Cancer cell, 6 1
Hongbing Zhang, G. Cicchetti, H. Onda, H. Koon, Kirsten Asrican, Natalia Bajraszewski, F. Vazquez, Christopher Carpenter, D. Kwiatkowski (2003)
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.The Journal of clinical investigation, 112 8
Ji Luo, B. Manning, L. Cantley (2003)
Targeting the PI3K-Akt pathway in human cancer: rationale and promise.Cancer cell, 4 4
J. Declue, A. Papageorge, J. Fletcher, S. Diehl, N. Ratner, W. Vass, D. Lowy (1992)
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosisCell, 69
Yong Zhang, Xinsheng Gao, L. Saucedo, B. Ru, B. Edgar, D. Pan (2003)
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 5
Alykhan Shamji, P. Nghiem, S. Schreiber (2003)
Integration of growth factor and nutrient signaling: implications for cancer biology.Molecular cell, 12 2
K. Podsypanina, Richard Lee, C. Politis, Ian Hennessy, Allison Crane, J. Puc, M. Neshat, Hong Wang, Lin Yang, J. Gibbons, Phil Frost, V. Dreisbach, J. Blenis, Z. Gaciong, Peter Fisher, C. Sawyers, Lora Hedrick-Ellenson, R. Parsons (2001)
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− miceProceedings of the National Academy of Sciences of the United States of America, 98
G. Bollag, D. Clapp, S. Shih, F. Adler, Youyan Zhang, P. Thompson, B. Lange, M. Freedman, F. McCormick, T. Jacks, K. Shannon (1996)
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cellsNature Genetics, 12
K. Cichowski, S. Santiago, Melanie Jardim, Bryan Johnson, T. Jacks (2003)
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.Genes & development, 17 4
C. Sawyers (2003)
Will mTOR inhibitors make it as cancer drugs?Cancer cell, 4 5
K. Inoki, Yong Li, Tian Xu, K. Guan (2003)
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.Genes & development, 17 15
Shane Donovan, W. See, J. Bonifas, D. Stokoe, K. Shannon (2002)
Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells.Cancer cell, 2 6
C. Marshall (1995)
Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activationCell, 80
Yuan Zhu, P. Ghosh, P. Charnay, D. Burns, L. Parada (2002)
Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor EnvironmentScience, 296
D. Kwiatkowski, Hongbing Zhang, Jennifer Bandura, Kristina Heiberger, M. Glogauer, N. el-Hashemite, H. Onda (2002)
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.Human molecular genetics, 11 5
A. Garami, F. Zwartkruis, T. Nobukuni, M. Joaquin, M. Roccio, Hugo Stocker, S. Kozma, E. Hafen, J. Bos, G. Thomas (2003)
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.Molecular cell, 11 6
N. Hay, N. Sonenberg (2004)
Upstream and downstream of mTOR.Genes & development, 18 16
M. Corradetti, K. Inoki, N. Bardeesy, R. DePinho, K. Guan (2004)
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.Genes & development, 18 13
I. Weinstein (2002)
Addiction to Oncogenes--the Achilles Heal of CancerScience, 297
C. Potter, Laura Pedraza, Tian Xu (2002)
Akt regulates growth by directly phosphorylating Tsc2Nature Cell Biology, 4
L. Kluwe, R. Friedrich, V. Mautner (1999)
Loss of NF1 allele in schwann cells but not in fibroblasts derived from an NF1‐associated neurofibromaGenes, 24
B. Manning, B. Manning, Andrew Tee, M. Logsdon, J. Blenis, L. Cantley, L. Cantley (2002)
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.Molecular cell, 10 1
E. Serra, S. Puig, David Otero, A. Gaona, H. Kruyer, E. Ars, X. Estivill, C. Lázaro (1997)
Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.American journal of human genetics, 61 3
P. Townes, G. Lovell (1961)
Hereditary methemoglobinemia: a new variant exhibiting dominant inheritance of methemoglobin A.Blood, 18
Proceedings of the National Academy of Sciences – Unpaywall
Published: Jun 3, 2005
Access the full text.
Sign up today, get DeepDyve free for 14 days.